** Shares of Massachusetts-based gene-editing firm Intellia Therapeutics NTLA.O up 8.4% at $11.71
** Company posts Q4 collaboration revenue of $12.9 million, beating analysts' estimates of $8.5 million, according to data compiled by LSEG
** Company's sales was mainly driven by collaboration revenue received under the Regeneron REGN.O agreements to develop gene-editing therapies for neurological and muscular disease
** Brokerage Leerink Partners expects shares to rise in the mid-single digits as company fleshed out details including operating expenses on call; NTLA expects 5%-10% lower operating expenses vs a year ago
** NTLA also expects operating expense below 2024 levels for the next several years as R&D spend sunsets with enrollment completion/trial conclusions in 2026 and beyond
** Company plans to submit a marketing application for a rare genetic disorder therapy, NTLA-2002, in H2 2026 to a potential U.S. launch in 2027
** "NTLA-2002 remains the most underappreciated asset in our coverage universe heading into upcoming pivotal (trial) data," brokerage says
** NTLA fell 61% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。